The DOI matches its Crossref record; 237 of the 237 references it cites were found in a registry or an index.
Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–237 of 237
A systematic review of bevacizumab efficacy in breast cancer
Kümler, I., Grummedal, O., & Nielsen, D. L. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.05.006 · Cited by 77
Comparative Oncogenomics Implicates the Neurofibromin 1 Gene (NF1) as a Breast Cancer Driver
Wallace, M. D., Pfefferle, A. D., Shen, L., McNairn, A. J., Cerami, E. G., Fallon, B. L., Rinaldi, V. D., Southard, T. L., Perou, C. M., & Schimenti, J. C. (2012) · Genetics · doi:10.1534/genetics.112.142802 · Cited by 74
Greenberg, S., & Rugo, H. S. (2010) · The Cancer Journal · doi:10.1097/ppo.0b013e3181d38514 · Cited by 73
STAT signaling in different breast cancer sub-types
Furth, P. A. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.03.023 · Cited by 73
Profiling phospho-signaling networks in breast cancer using reverse-phase protein arrays
Gujral, T. S., Karp, R. L., Finski, A., Chan, M. M., Schwartz, P. E., MacBeath, G., & Sorger, P. K. (2012) · Oncogene · doi:10.1038/onc.2012.378 · Cited by 72
Singh, M., Ramos, I., Asafu-Adjei, D. A., Quispe‐Tintaya, W., Chandra, D., Jahangir, A., Zang, X., Aggarwal, B. B., & Gravekamp, C. (2013) · Cancer Medicine · doi:10.1002/cam4.94 · Cited by 70
Yu, Y., Chou, R., Liang, J.-H., Chang, W.-J., Su, K., Tseng, Y.-J., Huang, W., Wang, S., & Hung, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061362 · Cited by 69
Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer
Grob, T. J., Heilenkötter, U., Geist, S., Paluchowski, P., Wilke, C., Jaenicke, F., Quaas, A., Wilczak, W., Choschzick, M., Sauter, G., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2092-7 · Cited by 68
Risk of second breast cancer in female Hodgkin’s lymphoma survivors: a meta-analysis
Ibrahim, E. M., Abouelkhair, K. M., Kazkaz, G. A., Elmasri, O. A., & Al‐Foheidi, M. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-197 · Cited by 68
Dees, E. C., Baker, S. D., O’Reilly, S., Rudek, M. A., Davidson, S. B., Aylesworth, C. A., Elza-Brown, K., Carducci, M. A., & Donehower, R. C. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.664.11.2 · Cited by 68
PD-L1 expression and tumor-infiltrating lymphocytes
Schalper, K. A. (2014) · OncoImmunology · doi:10.4161/onci.29288 · Cited by 67
Molecular Pathways: PI3K Pathway Targets in Triple-Negative Breast Cancers
Gordon, V. L., & Banerji, S. O. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0274 · Cited by 64
Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer
Sánchez‐Muñoz, A., Gallego, E., de Luque, V., Perez‐Rivas, L. G., Vicioso, L., Ribelles, N., Lozano, J., & Alba, E. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-136 · Cited by 63
Tilch, E., Seidens, T., Cocciardi, S., Reid, L., Byrne, D. J., Simpson, P. T., Vargas, A. C., Cummings, M. C., Fox, S. B., Lakhani, S. R., et al. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2798-1 · Cited by 59
Are Triple-Negative and Basal-Like Breast Cancer Synonymous?
Rakha, E. A., Ellis, I. O., & Reis-Filho, J. S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1943 · Cited by 59
Jovanović, B., Beeler, J. S., Pickup, M. W., Chytil, A. M., Gorska, A. E., Ashby, W. J., Lehmann, B. D., Zijlstra, A., Pietenpol, J. A., & Moses, H. L. (2014) · Breast Cancer Research · doi:10.1186/bcr3684 · Cited by 58
cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer
Sohn, J., Liu, S., Parinyanitikul, N., Lee, J., Hortobágyi, G. N., Mills, G. B., Ueno, N. T., & Gonzalez-Angulo, A. M. (2014) · Journal of Cancer · doi:10.7150/jca.9696 · Cited by 58
Linking signaling pathways to transcriptional programs in breast cancerPreprint
Osmanbeyoglu, H. U., Pelossof, R., Bromberg, J., & Leslie, C. S. (2014) · Genome Research · doi:10.1101/gr.173039.114 · Cited by 58
Cabezón, T., Gromova, I., Gromov, P., Serizawa, R., Wielenga, V. T., Kroman, N. T., Celis, J. E., & Moreira, J. M. A. (2012) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m112.019786 · Cited by 52
Hong, S., Hedayati, M. A., Hobbs, R. F., Shao, C., Bruchertseifer, F., Morgenstern, A., DeWeese, T. L., & Sgouros, G. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0108 · Cited by 50
Al‐Ejeh, F., Miranda, M. S., Shi, W., Simpson, P. T., Song, S., Vargas, A. C., Saunus, J. M., Smart, C. E., Mariasegaram, M., Wiegmans, A. P., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1865 · Cited by 48
Self-citationAudeh, W. (2014) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s39765 · Cited by 42
Poly(ADP-Ribose) Polymerase 1 Modulates the Lethality of CHK1 Inhibitors in Carcinoma Cells
Mitchell, C., Park, M., Eulitt, P. J., Chen, Y., Yacoub, A., & Dent, P. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.067199 · Cited by 39
Ganesan, P., Moulder, S. L., Lee, J. J., Jankú, F., Valero, V., Zinner, R., Naing, A., Fu, S., Tsimberidou, A. M., Hong, D. S., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0358 · Cited by 38
C-kit and PDGFRA gene mutations in triple negative breast cancer.
Zhu, Y., Wang, Y., Guan, B., Rao, Q., Wang, J., Ma, H., Zhang, Z., & Zhou, X. (2014) · PubMed Central · Cited by 36
Improved network performance via antagonism: From synthetic rescues to multi‐drug combinations
Motter, A. E. (2010) · BioEssays · doi:10.1002/bies.200900128 · Cited by 36
Cyclin-dependent kinase 4/6 inhibitors in breast cancer therapy
Migliaccio, I., Leo, A. D., & Malorni, L. (2014) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000129 · Cited by 35
The role of VEGF in triple-negative breast cancer: where do we go from here?
Dent, S. F. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp410 · Cited by 32
Gaule, P., Crown, J. P., O’Donovan, N., & Duffy, M. J. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.938050 · Cited by 30
High expression of MAGE-A10 cancer-testis antigen in triple-negative breast cancer
Tanja, B. Č., Spagnoli, G. C., Juretić, A., Jakić‐Razumović, J., Podolski, P., & Šarić, N. (2011) · Medical Oncology · doi:10.1007/s12032-011-0120-9 · Cited by 29
Targeting a cell state common to triple‐negative breast cancers
Muellner, M. K., Mair, B., Ibrahim, Y. H., Kerzendorfer, C., Lechtermann, H., Jessen‐Trefzer, C., Klepsch, F., Müller, A. C., Leitner, E., Macho‐Maschler, S., et al. (2015) · Molecular Systems Biology · doi:10.15252/msb.20145664 · Cited by 26
Defining the expressed breast cancer kinome
Midland, A. A., Whittle, M. C., Duncan, J. S., Abell, A. N., Nakamura, K., Zawistowski, J. S., Carey, L., Earp, H. S., Graves, L. M., Gomez, S. M., et al. (2012) · Cell Research · doi:10.1038/cr.2012.25 · Cited by 25
PARP inhibitor reduces proliferation and increases apoptosis in breast cancer cells.
Shi, Y., Zhou, F., Jiang, F., Lu, H., Wang, J., & Cheng, C. (2014) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.1000-9604.2014.02.13 · Cited by 18
Screens, maps & networks: from genome sequences to personalized medicine
Sandmann, T., & Boutros, M. (2012) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2012.02.001 · Cited by 17
Erratum to: High expression of MAGE-A10 cancer-testis antigen in triple-negative breast cancer
Badovinac-Črnjević, T., Spagnoli, G. C., Juretić, A., Jakić‐Razumović, J., Podolski, P., & Šarić, N. (2012) · Medical Oncology · doi:10.1007/s12032-012-0172-5 · Cited by 15
Mishra, S. K., Bhowmick, S. S., Chua, H. E., Zhang, F., & Zheng, J. (2015) · BMC Systems Biology · doi:10.1186/1752-0509-9-s1-s4 · Cited by 10
Margolin, A. A. (2013) · Cited by 4
Cited by
The calcium–cancer signalling nexus
Monteith, G. R., Prevarskaya, N., & Roberts-Thomson, S. J. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.18 · Cited by 635
Targeted therapies in breast cancer: New challenges to fight against resistance
Masoud, V., & Pagès, G. (2017) · World Journal of Clinical Oncology · doi:10.5306/wjco.v8.i2.120 · Cited by 357
Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapies
Lee, A., & Djamgoz, M. B. A. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.11.003 · Cited by 354
Targeted exosome‐encapsulated erastin induced ferroptosis in triple negative breast cancer cells
Yu, M., Gai, C., Li, Z., Ding, D., Zheng, J., Zhang, W., Lv, S., & Li, W. (2019) · Cancer Science · doi:10.1111/cas.14181 · Cited by 345
Recent advances in targeted strategies for triple-negative breast cancer
Zhu, S., Wu, Y., Song, B., Yi, M., Yan, Y., Mei, Q., & Wu, K. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01497-3 · Cited by 331
Metadata
- Authors
- Kalimutho, M., Parsons, K., Mittal, D., López, J. A., Srihari, S., & Khanna, K. K.
- Venue
- Trends in Pharmacological Sciences
- Publisher
- Elsevier BV
- Published
- 2015-12
- Volume
- 36
- Issue
- 12
- Pages
- 822-846
- ISSN
- 0165-6147 (ISSN-L)
- OpenAlex
- W1857266517
- Cited by
- 294
- References
- 237
- FWCI
- 2.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.